Our team provides expertise in evaluating abuse liability for new chemical entities (NCE) and abuse-deterrent formulations (ADF). We can assist in all premarket phases of program or study development, from initial planning to regulatory submission. With extensive research experience, we have contributed to the design and assessment of over one hundred Phase 1 studies, including more than 50 abuse liability studies, as well as first-in-man, pharmacokinetic, drug/alcohol interaction, and proof of concept studies.
Altreos Research Partner
Headquarters
Canada